Reducing the length of hospital stay (lohs) of elderly psychiatric patients is of great importance. The role of electroconvulsive therapy (ect) in this process is still unclear.
AIM: To explore the impact of ect on the lohs in elderly (>60 years) with major depressive disorder (mdd).
METHOD: All charts of patients with a diagnosis of mdd, discharged from geriatric psychiatry wards from April 2009 to December 2017 were gathered. Two groups were further explored: those who did not receive ect although available (no-ect; n = 170) and those who received ect within 3 weeks of admission (ect<3wks; n = 60). As primary outcome measure lohs was used.
RESULTS: No significant difference in lohs was observed between the no-ect group and the ect< 3wks group (mean 90.3 (sd: 109.2) and 86.4 (sd: 70.9) days; p=0.798). The distribution of diagnoses in the groups was significantly different (p<0.001) with psychotic features in 35.2% of patients in the no-ect group and 72% in the ect<3wks group. CONCLUSIONS Electroconvulsive therapy did not significantly change lohs in elderly with mdd. Time until starting ect and the presence of psychotic features appear to be important confounders that need to be taken into account in further research.
Download full-text PDF |
Source |
---|
J ECT
January 2025
From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA.
Background: Electroconvulsive therapy (ECT) is an effective treatment for treatment-resistant depression (TRD). There are limited data on the improvement of anxiety symptoms in patients receiving ECT for TRD.
Objective: The aim of the study was to examine the extent to which anxiety symptom severity improves, relative to improvements in depressive symptoms, in TRD patients receiving an acute course of ECT.
There remains a scarcity of studies to evaluate the treatment effect of electroconvulsive therapy (ECT). Functional near-infrared spectroscopy (fNIRS) offers a cost-effective method to measure cerebral hemodynamics. This study used fNIRS to evaluate the effect of ECT in patients suffering from schizophrenia or bipolar disorder (manic phase).
View Article and Find Full Text PDFJ ECT
January 2025
From the Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN.
Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing.
View Article and Find Full Text PDFJ ECT
January 2025
From the Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Objectives: This study investigates repeated oral esketamine as a substitution strategy for maintenance electroconvulsive therapy (M-ECT) in eight patients with treatment-resistant depression (TRD).
Methods: In a 6-week dosing phase, esketamine was titrated from 0.5 or 1.
Brain Stimul
January 2025
Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!